Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01322217 · ClinicalTrials.gov registry record
Managerial Database II
A clinical trial of Acquired Immunodeficiency Syndrome, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- 513
- Enrollment target
- 5
- Study locations
NCT01322217 is a study of Acquired Immunodeficiency Syndrome that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 513 participants, above the 187-participant average among 17 other Acquired Immunodeficiency Syndrome trials with a reported enrollment target (174% higher). The trial reports 5 study locations across 5 states.
The verdict
NCT01322217, a study of Acquired Immunodeficiency Syndrome, has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- 513 participants
- Enrollment target
- 5
- Study locations
Study Summary
This study will collect information on health status and risk behaviors, as well as basic demographic and biomedical information for a group of HIV positive adolescents receiving care at sites newly participating in ATN III.
Conditions Studied
Study Locations (5)
Colorado
- University of Colorado Denver - Aurora
Maryland
- Johns Hopkins University - Baltimore
Massachusetts
- The Fenway Institute-Fenway Health - Boston
Michigan
- Wayne State University-Children's Hospital of Michigan - Detroit
Texas
- Baylor College of Medicine - Pediatrics Allergy and Immunology - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 513 participants |
| Start Date | 2011-04 |
| Est. Completion | 2012-06 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01322217
The ClinicalTrials.gov registry entry for NCT01322217 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 513 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 187-participant average among 17 other Acquired Immunodeficiency Syndrome trials with a reported enrollment target (174% higher). The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Acquired Immunodeficiency Syndrome appearing as the primary indexed condition, and to 0 interventions.
NCT01322217 reports 5 study locations spanning 5 distinct geographic areas - top geographies include Colorado, Maryland, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT01322217 about?
NCT01322217 is a clinical study titled "Managerial Database II". This study will collect information on health status and risk behaviors, as well as basic demographic and biomedical information for a group of HIV positive adolescents receiving care at sites newly participating in ATN III.
What is the current status of trial NCT01322217?
This trial is currently completed. The enrollment target is 513 participants. The study started on 2011-04. Estimated completion is 2012-06.
What conditions does trial NCT01322217 study?
This clinical trial studies the following conditions: Acquired Immunodeficiency Syndrome.
Who is sponsoring clinical trial NCT01322217?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01322217 being conducted?
This trial has 5 study locations across Colorado, Maryland, Massachusetts, Michigan, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acquired Immunodeficiency Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Cytotoxic T Lymphocytes in Treating Patients With Malignancies With BK and/or JC Virus
RECRUITING · Phase 2
-
Safety, Immunogenicity, Efficacy of Ad26.Mos4.HIV, MVA-BN-HIV and PGT121, PGDM1400, and VRC07-523LS in HIV-1-Infected Adults
ACTIVE NOT RECRUITING · Phase 1
-
Twins Study of Gene Therapy for HIV Infection
COMPLETED · Phase 1
-
Mesalamine to Reduce T Cell Activation in HIV Infection
COMPLETED · Phase 4
-
HIV Prevention Intervention for Couples
COMPLETED · Phase 2
-
Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Followed by Treatment With Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced Adults
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.